<DOC>
	<DOCNO>NCT02099604</DOCNO>
	<brief_summary>The purpose study show superiority 4 week lead-in phase Vitamin D follow 48 week combination Vitamin D PEG-IFN plus RBV comparison standard PEG-IFN + RBV untreated Egyptian patient chronic hepatitis C , sustain virological response ( SVR ) 3 month end treatment ( week 60 ) .</brief_summary>
	<brief_title>Efficacy Safety Combination Vitamin D With Standard Care Egyptian Patients With Untreated Chronic Hepatitis C</brief_title>
	<detailed_description>- Method : Phase III , randomize , open-label superiority clinical trial , among Egyptian patient chronic hepatitis C. - Treatment strategy : Vitamin D Arm : Vitamin D 4 week lead-in phase follow Vitamin D combination PEG-INF plus RBV 48 week . Standard Care Arm : PEG-INF plus RBV 48 week . - Main outcome : Proportion patient Sustained Virological Response ( SVR ) define HCV RNA detection limit base quantitative PCR 12 week stop treatment . - Sample Size : 520 patient ( 260 per arm ) - Enrollment period : 12 month - Patient 's participation duration : 62 week ( SOC Arm ) , 66 week ( Vit-D Arm ) - Statistical analysis : The superiority vitamin D arm test standard PEG IFN + RBV combination . 260 patient arm give 80 % power document 12 % difference SVR rate experimental ( Vitamin D ) control ( standard treatment ) arms.. A futility analysis plan study , order able interrupt trial prematurely case preliminary result show lack efficacy vitamin D. This analysis perform half patient , thus 260 patient ( 130 patient per arm ) , week 12/14 week criterion ( HCV RNA viral load W12/W14 ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Common National Program Viral Hepatitis Age : 18 year 60 year Positive HCV antibody use third generation test Detectable HCV RNA PCR Liver biopsy show chronic hepatitis either METAVIR score F1 elevate liver enzyme score F2/F3 Naïve treatment PEGIFN RBV HBs antigen negative Prothrombin time ≥60 % , normal bilirubin , alphafoeto protein &lt; 3*normal range laboratory , antinuclear antibody &lt; 1/160 Effective contraception treatment period ; breastfeed Specific trial Prior approval Ministry Health treat part National Program allocation PegIFN α2b treatment Living &lt; 100 km Cairo able come centre every week treatment Signed informed consent willingness participate trial Naïve treatment vitamin D ( receive vitamin D le 30 consecutive day 3 month precede inclusion ) Biopsy slide validate NHTMRI pathologist Common National program Viral Hepatitis Serious comorbid condition severe hypertension , heart failure , significant coronary heart disease , poorly control diabetes ( HbA1C &gt; 8 % ) , chronic obstructive pulmonary disease Major uncontrolled depressive illness Solid transplant organ ( renal , heart , lung ) Untreated thyroid disease History previous antiHCV therapy Body mass index ( BMI ) great 30 kg/m² Known human immunodeficiency virus ( HIV ) coinfection : although HIV test propose do , patient know HIV coinfection include trial AntiHCV therapy contraindication : hypersensitivity one two drug ( PEGIFN , RBV ) pregnancy unwilling comply adequate contraception breastfeed neutropenia ( &lt; 1500/mm3 ) anaemia ( &lt; 11g/dL woman ; &lt; 12g/dL men ) thrombocytopenia ( &lt; 100,000/mm3 ) elevate creatinin ( &gt; 1.5mg/dL ) concomitant liver disease hepatitis C ( immunoactive chronic hepatitis B , autoimmune hepatitis , alcoholic liver disease , hemochromatosis , alpha1 antitrypsin deficiency , Wilson disease ) liver biopsy show severe steatosis ( &gt; 66 % ) steatohepatitis ; decompensated cirrhosis ( Child Pugh &gt; A ) ; hepatocellular carcinoma , METAVIR score F4 . TSH &gt; 5 mU/L Specific trial Patients allocate PegIFN alpha 2a treatment Hypersensitivity vitamin D Vitamin D contraindication : hypercalcaemia ( fast calcaemia &gt; 105 mg/L 2.62 mmol/L ) ratio calciuria / creatininuria ( fast ratio &gt; 1 mmol Ca/mmol creatinin ) hyperphosphatemia ( &gt; 1.5 mmol/L ) calcium lithiasis patient treat thiazide diuretic ( risk hypercalcaemia vitamin D treatment ) patient treat glucocorticoïds ( decrease vitamin D efficacy ) postmenopausal woman treat vitamin D calcium osteoporosis Treatment vitamin D 30 consecutive day 3 month precede inclusion trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hepatitis C - Genotype 4</keyword>
	<keyword>SVR ( Sustained Virological Response )</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Treatment Naïve</keyword>
</DOC>